Cargando…

Association between cytokines and functional, hemodynamic parameters, and clinical outcomes in pulmonary arterial hypertension

To assess the relationship of cytokines with functional and clinical outcomes in pulmonary arterial hypertension (PAH). Endothelial dysfunction and vascular inflammation are characteristic of PAH. We investigated whether markers of angiogenesis and inflammation associated with functional, hemodynami...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joshi, Aditya A., Davey, Ryan, Rao, Youlan, Shen, Kai, Benza, Raymond L., Raina, Amresh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153541/ https://www.ncbi.nlm.nih.gov/pubmed/30036135 http://dx.doi.org/10.1177/2045894018794051

Ejemplares similares

Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension
por: Davey, Ryan, et al.
Publicado: (2017)

Hemodynamic monitoring in heart failure and pulmonary hypertension: From analog tracings to the digital age
por: Davey, Ryan, et al.
Publicado: (2016)

Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension
por: Verlinden, Nathan J., et al.
Publicado: (2020)

Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series
por: Raina, Amresh, et al.
Publicado: (2017)

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013)

Data on clinical and economic burden associated with pulmonary arterial hypertension related hospitalizations in the United States
por: Chaturvedi, Abhishek, et al.
Publicado: (2020)

Risk assessment in pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2016)

Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study
por: Benza, Raymond L., et al.
Publicado: (2017)

The Evolution of Risk Assessment in Pulmonary Arterial Hypertension
por: Murthy, Sandhya, et al.
Publicado: (2021)

Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension
por: Benza, Raymond L., et al.
Publicado: (2021)

Novel approach to classifying patients with pulmonary arterial hypertension using cluster analysis
por: Parikh, Kishan S., et al.
Publicado: (2017)

Computational Simulator Models and Invasive Hemodynamic Monitoring as Tools for Precision Medicine in Pulmonary Arterial Hypertension
por: Manzi, Giovanna, et al.
Publicado: (2021)

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Humbert, Marc, et al.
Publicado: (2019)

Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes
por: Burger, Charles D, et al.
Publicado: (2017)

Hemodynamic trajectories and outcomes in patients with pulmonary arterial hypertension
por: Amsallem, Myriam, et al.
Publicado: (2020)

Is hyponatremia associated with mortality in pulmonary arterial hypertension?
por: Rudkovskaia, Anastasiia A., et al.
Publicado: (2018)

Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design
por: Benza, Raymond L., et al.
Publicado: (2022)

Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension
por: Morland, Kellie, et al.
Publicado: (2021)

Reduced RVSWI Is Associated With Increased Mortality in Connective Tissue Disease Associated Pulmonary Arterial Hypertension
por: Clapham, Katharine R., et al.
Publicado: (2020)

Vorticity for the assessment of pulmonary vascular hemodynamics in pulmonary arterial hypertension
por: Honeyman, Alexander, et al.
Publicado: (2014)

The relationship between T‐wave peak‐to‐end interval and hemodynamic parameters in patients with pulmonary arterial hypertension
por: Elitok, Ali, et al.
Publicado: (2020)

Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19
por: Franco, Veronica, et al.
Publicado: (2020)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review
por: Wesley Milks, Michael, et al.
Publicado: (2021)

Do single or sequential measurements of leptin and adiponectin in plasma have prognostic value in pulmonary arterial hypertension?
por: Tonelli, Adriano R., et al.
Publicado: (2017)

Are you Coupled? Hemodynamic Phenotyping in Pulmonary Hypertension
por: Friedman, Samuel H, et al.
Publicado: (2022)

Nitric Oxide Stroke Volume Index as a New Hemodynamic Prognostic Parameter for Patients with Pulmonary Arterial Hypertension
por: Barańska-Pawełczak, Karolina, et al.
Publicado: (2020)

Study of the effect of Occlutech Atrial Flow Regulator on symptoms, hemodynamics, and echocardiographic parameters in advanced pulmonary arterial hypertension
por: Sivakumar, Kothandam, et al.
Publicado: (2021)

Complexity of macrophage migration inhibitory factor (MIF) and other angiogenic biomarkers profiling in pulmonary arterial hypertension
por: Marshall, Jeffrey D., et al.
Publicado: (2017)

Prediction of Prognostic Hemodynamic Indices in Pulmonary Hypertension Using Non-Invasive Parameters
por: Mańczak, Rafał, et al.
Publicado: (2020)

Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary Arterial Hypertension
por: Brash, Lauren, et al.
Publicado: (2018)

Monitoring of Hemodynamics With Right Heart Catheterization in Children With Pulmonary Arterial Hypertension
por: Grynblat, Julien, et al.
Publicado: (2023)

Novel Mutations in BMPR2, ACVRL1 and KCNA5 Genes and Hemodynamic Parameters in Patients with Pulmonary Arterial Hypertension
por: Pousada, Guillermo, et al.
Publicado: (2014)

Pulmonary arterial hypertension in Saudi Arabia: Patients' clinical and physiological characteristics and hemodynamic parameters. A single center experience
por: Idrees, MM, et al.
Publicado: (2014)

Complex transposition of the great arteries with pulmonary arterial hypertension and giant pulmonary artery aneurysm
por: Leong, Kai’En, et al.
Publicado: (2018)

Data-driven computational models of ventricular-arterial hemodynamics in pediatric pulmonary arterial hypertension
por: Tossas-Betancourt, Christopher, et al.
Publicado: (2022)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

Risk assessment in patients with functional class II pulmonary arterial hypertension: Comparison of physician gestalt with ESC/ERS and the REVEAL 2.0 risk score
por: Sahay, Sandeep, et al.
Publicado: (2020)

MicroCT analysis of vascular morphometry: a comparison of right lung lobes in the SUGEN/hypoxic rat model of pulmonary arterial hypertension
por: Faight, Erin M., et al.
Publicado: (2017)

Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry
por: Chung, Lorinda, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fk5lqdo8pjpn6fdor8frhs5guv